Orion - Company Announcement

Annual Summary of Stock Exchange Releases published in 2010

ORION CORPORATION    STOCK EXCHANGE RELEASE  19 JAN 2011  AT 11.00
EET

In accordance with Chapter 2, Section 10 c of the Finnish Securities Market Act,
Orion Corporation publishes an Annual Summary of the stock exchange releases
published by the company in 2010. The releases are available on the internet
website of Orion Corporation, at http://www.orion.fi/sereleases.
Orion points out that part of the information in the releases can have become
out-dated.

Stock Exchange Releases in 2010

Jan 4th 2010  200,000 Orion A-shares converted into B-shares

Jan 19th 2010 ORION CORPORATION: Recommendation by the Nomination Committee
              concerning Board of Directors to be elected by the 2010 AGM of
              Orion Corporation, 19 Jan 2010

Jan 20th 2010 Annual Summary of Stock Exchange Releases published in 2009

Feb 1st 2010  Orion invites analysts and media to Financial Statement Release
              conference on 9 February 2010

Feb 9th 2010  Orion Group Financial Statement Release of 2009

Feb 9th 2010  Notice to the Annual General Meeting of Orion Corporation

Feb 18th 2010 The Board of Directors of Orion Corporation decided on an
              incentive plan for key persons

Mar 1st 2010  Orion Corporation: Transfer of 65,606 own B-shares on 1 March 2010

Mar 2nd 2010  Orion Group Annual Report 2009 published

Mar 11th 2010 Orion Corporation: Member of the Board of Directors of Orion
              Corporation Leena Palotie passed away

Mar 24th 2010 Orion Corporation: Decisions by the AGM on 24 March 2010

Mar 24th 2010 Orion Corporation: Matti Kavetvuo Vice Chairman of the Board of
              Directors. Compositions of Board committees

Apr 1st 2010  Orion comments on FDA release on Stalevo

Apr 8th 2010  Amendment of Section 12 of Articles of Association entered in the
              Trade Register

Apr 15th 2010 Orion invites analysts and media to Q1 news conference on Tuesday
              27 April 2010

Apr 20th 2010 Dexmedetomidine Phase III program completed with positive results

Apr 27th 2010 Orion Group Interim Report January-March 2010

Apr 30th 2010 1,700,000 Orion A-shares converted into B-shares

May 18th 2010 Change in Orion Group Executive Management Board as of 1 Oct 2010

May 18th 2010 Decision by the Board of Directors to repurchase own shares

Jun 1st 2010  1,100,000 Orion A-shares converted into B-shares

Jun 14th 2010 Orion upgrades full-year outlook for 2010

Jun 15th 2010 Composition of R&D Committee as of 15 June 2010

Jun 17th 2010 20,138 Orion A-shares converted into B-shares

Jun 22nd 2010 Orion and Sun settle patent dispute

Jul 19th 2010 Orion invites analysts and media to Q2 news conference on Tuesday
              10 August 2010

Aug 10th 2010 Orion Corporation's publication schedules for financial reporting
              in 2011

Aug 10th 2010 Orion Group Interim Report January-June 2010

Aug 13th 2010 435,019 Orion A-shares converted into B-shares

Aug 20th 2010 Orion comments on today's FDA release on safety review of Stalevo®

Sep 1st 2010  Orion: Change in the holding of own shares

Sep 24th 2010 Change in Orion Group Executive Management Board as of 1 Jan 2011

Oct 11th 2010 Orion invites analysts and media to Q3 news conference on Tuesday
              26 October 2010

Oct 15th 2010 Disclosure Under Chapter 2 Section 9

Oct 20th 2010 European Medicines Agency has initiated the review of Orion's
              dexmedetomidine marketing authorisation application

Oct 26th 2010 Orion Group Interim Report January-September 2010

Nov 1st 2010  Composition of the Nomination Committee of Orion Corporation

Nov 12th 2010 321,946 Orion A-shares converted into B-shares

Dec 15th 2010 Orion comments on ANDA filed by Mylan Pharmaceuticals Inc. for a
              generic version of Orion's proprietary drug Comtan® (entacapone)
              in the United States




Orion Corporation


Timo Lappalainen  Olli Huotari
President and CEO SVP, Corporate Functions






Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo
Homepage: www.orion.fi




Orion is an innovative European R&D-based pharmaceutical and diagnostic company
with a special emphasis on developing medicinal treatments and diagnostic tests
for global markets. Orion develops, manufactures and markets human and
veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic
tests. Orion's pharmaceutical R&D focuses on the following core therapy areas:
central nervous system drugs, cancer and critical care drugs, and Easyhaler®
pulmonary drugs.

The Group's net sales in 2009 amounted to EUR 772 million. The Company invested
EUR 95 million in research and development. At the end of 2009, the Group had a
total of 3,100 employees, of whom 2,500 worked in Finland and 600 in other
European countries. Orion's A and B shares are listed on NASDAQ OMX Helsinki.




[HUG#1480486]